Endo Int'l (ENDP) Tops Q1 EPS by 13c; Reaffirms

Endo Int'l (NASDAQ: ENDP) reported Q1 EPS of $1.23, $0.13 better than the analyst estimate of $1.10. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion.

• First-quarter 2017 revenues increased 8 percent from prior year to $1,038 million
• First-quarter 2017 U.S. Generic Pharmaceuticals revenue increased 24 percent to $722 million
• First-quarter 2017 reported $0.74 diluted (GAAP) loss per share from continuing operations
• First-quarter 2017 adjusted diluted earnings per share (EPS) from continuing operations increased 14 percent to $1.23
• First-quarter 2017 reported (GAAP) consolidated net loss of $174 million
• First-quarter 2017 adjusted EBITDA increased 21 percent to $478 million
• Company reaffirms 2017 full-year revenues, adjusted EBITDA and adjusted diluted EPS financial guidance

For earnings history and earnings-related data on Endo Int'l (ENDP) click here.

You May Also Be Interested In

• Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
• Greene County Bancorp, Inc. (GCBC) Reports Q3 EPS of $0.34
• Canadian Pacific Kansas City (CP) Tops Q1 EPS by 93c